Raymond James reiterates Strong Buy rating on Scholar Rock stock ahead of PDUFA date

Published 06/08/2025, 18:48
Raymond James reiterates Strong Buy rating on Scholar Rock stock ahead of PDUFA date

Investing.com - Raymond (NSE:RYMD) James maintained its Strong Buy rating and $53.00 price target on Scholar Rock (NASDAQ:SRRK) following the company’s second-quarter results and corporate update. The stock, which has surged over 330% in the past year and currently trades at $34.79, aligns with the broader analyst consensus of "Strong Buy" with price targets ranging from $46 to $57. According to InvestingPro analysis, the stock appears overvalued at current levels.

The research firm’s decision comes as Scholar Rock approaches a September 22nd PDUFA (Prescription Drug User Fee Act) date for its drug candidate apitegromab.

In its corporate update, Scholar Rock disclosed FDA inspection observations at two third-party Contract Development and Manufacturing Organization (CDMO) facilities involved in Chemistry, Manufacturing, and Controls (CMC) activities for apitegromab.

Raymond James noted these inspection observations in its analysis but maintained its positive outlook on the company’s prospects.

The firm’s $53 price target remains unchanged, reflecting continued confidence in Scholar Rock despite the disclosed FDA observations at the manufacturing facilities.

In other recent news, Scholar Rock Holding Corp reported its second-quarter 2025 earnings, which showed an earnings per share (EPS) of -0.98. This figure was below analysts’ expectations of -0.66, resulting in a 48.48% negative surprise. The earnings miss has raised concerns among investors about the company’s financial performance. Additionally, the stock experienced a decline in premarket trading following the announcement. These developments underscore the importance of earnings and revenue results for investors assessing the company’s financial health. As the company navigates these challenges, market participants will likely keep a close watch on future earnings reports.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.